Company intelligence / Profile preview
Spinal Restoration, Inc.
- Ownership
- Private
- Development stage
- Phase 3
Overview
Spinal Restoration developed the Biostat System, an intradiscal biologic therapy using BIOSTAT BIOLOGX Fibrin Sealant delivered via a proprietary device. The system was the first intradiscal biologic therapy for discogenic pain to complete enrollment in a Phase III IND study. As of late 2012, the company was preparing to submit a Biologic License Application (BLA) to the FDA based on positive preclinical and clinical data. No recent updates suggest further development or commercialization since that time.
- Therapeutic areas
- Neurology
- Modalities
- Biologic tissue sealant (human-derived fibrin sealant)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Spinal Restoration, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spinal Restoration, Inc..